Biotech Co.* (Country/Symbol) |
Pharma Co. (Country/Symbol) |
Product |
Amount (M) |
Terms/Details (Date)** |
Access Pharmaceuticals Inc. (OTC BB: AXCS) |
Mipharm SpA (Italy) |
Various formulations of amlexenox for treating several diseases, including mucositis, oral lichenplanus and atopic dermatitis |
ND |
Mipharm gains marketing rights for Italy, Switzerland, Turkey and Lebanon; Access has granted Mipharm manufacturing rights for Europe for the products; Mipharm will make an equity investment in Access, and pay up-front licensing fees and milestones; Access also will receive a percentage of product sales in covered territories; Mipharm receives an option to license other Access products in dermatology and gynecology (3/00) |
Angstrom Pharmaceuticals Inc.* |
Calbiochem-Novabio Corp.* |
Catalogue of reagents based on the urokinase plasminochem gene activator and its receptor |
ND |
Calbiochem will distribute the reagents worldwide (1/00) |
Cell Pathways Inc. (CLPA) |
Innovex; Livingston Healthcare Services Inc.; and Lash Group Inc. |
Aptosyn (exisulind; orally active drug designed to induce apoptosis in precancerous cells; inhibits a cyclic GMP phosphodiesterase); under consideration at FDA for familial adenomatosus polyposis |
ND |
Cell Pathways signed three agreements for U.S. sales and distribution of Aptosyn; Innovex will hire and train a dedicated sales force for Cell Pathways to launch and promote Aptosyn in the U.S.; Livingston will be responsible for customer service and other administrative tasks; Lash Group will develop and implement support services for Aptosyn (1/00) |
ChemBlock International* (Russia) |
ChemDiv Inc.* |
Compound libraries |
ND |
ChemDiv gains exclusive worldwide distribution rights to ChemBlock's collection for use with its Lead Generation and Rapid Analog Delivery programs (2/00) |
Commonwealth Biotechnologies Inc. (CBTE) |
CosmoBio Co. Ltd. and KN International LLC (both of Japan) |
Commonwealth's AccuTrac DNA sequencing aid |
ND |
CosmoBio and KN gain non-exclusive licenses to market the product (2/00) |
Genomic Solutions Inc.* |
PerkinElmer Inc. (NYSE:PKI) |
Biochips and proteomic systems |
ND |
PerkinElmer will have exclusive distribution rights worldwide with the exception of the U.S., UK and Japan; in those countries PerkinElmer and Genomic Solutions will sell co-branded products; companies also will collaborate to leverage intellectual property and technologies; PerkinElmer receives an equity stake in Genomic Solutions, with an option to acquire control (1/00) |
Genzyme General (GENZ) |
Biobras SA (Brazil) |
Thyrogen (hormone for follow-up screening of patients treated for thyroid cancer) |
ND |
Biobras will exclusively distribute and market Thyrogen in Brazil; Genzyme will receive a series of payments (2/00) |
Hemispherx Biopharma Inc. (AMEX:HEB) |
Biovail Corp. International (Canada) |
Ampligen, for treatment of chronic fatigue immune deficiency syndrome (CFIDS), also known as myalgic encephalomyelitis |
$2 |
Biovail gains exclusive rights to market Ampligen in Canada in return for purchasing $2M in Hemispherx common shares (2/00) |
Kreatech Biotechnology B.V.* (the Netherlands) |
NEN Life Science Products* |
ULS, a chemical labeling technique, for use with microarrays |
ND |
NEN is the exclusive worldwide marketing partner, with rights to develop and sell products for both the research and diagnostic markets (2/00) |
LifeCell Corp. (LIFC) |
Obagi Medical Products* |
Cymetra, which consists of small particles of processed acellular human tissue matrix for non-surgical soft-tissue replacement |
$1 |
Obagi gains rights to co-promote product to office-based dermatologists and plastic surgeons in exchange for a $1M up-front fee; Obagi will receive a co-promotion fee based on a percentage of net sales; the companies jointly will oversee the development and implementation of marketing programs; LifeCell will market Cymetra directly to hospitals and a subset of private office accounts through its own sales force (2/00) |
Medarex Inc. (MEDX) |
Scil Biomedicals GmbH (Germany) |
Mederax's MDX-RA for prevention of secondary cataracts, and MDX-210 for the treatment of HER2 overexpressing tumors |
$29 |
Scil licensed development and marketing rights in Europe and the Near East for $4M up front plus royalties on sales; Scill also committed up to $25M to support further development in its territories and in North America, but is entitled to receive milestones from Medarex; Scil will pay 100% of remaining development costs for MDX-RA; for MDX-210, Scil received commercial rights other than for cellular therapy; Medarex can opt to pay a portion of development costs for MDX-210 and retain all commercial rights in its territory, or it can elect for Scil to pay all costs up to $17M and give Scil co-marketing rights in the U.S.; excess costs would be shared equally (1/00) |
Myriad Genetics Inc. (MYGN) |
Falco Biosystems Ltd. (Japan) |
Myriad's BRACAnalysis test for breast and ovarian cancer risk and its CardiaRisk test for hypertension and cardiovascular disease |
$3 |
Falco paid $3M up front, and will pay royalties on sales; additional products may be added, at Falco's option; Falco will hold exclusive license in Japan for six years, provided performance milestones are met; agreement is renewable after initial six-year term (2/00) |
Myriad Genetics Inc. (MYGN) |
Rosgen Ltd. (UK) |
Myriad's BRACAnalysis genetic test for breast and ovarian cancer risk |
ND |
Five-year, renewable agreement includes up-front fee, milestones and royalties on sales in the UK and Ireland (3/00) |
NeoRx Corp. (NERX) |
International Isotopes (INIS) |
NeoRx's Skeletal Targeted Radiotherapy product for treatment of multiple myeloma |
$1.3 |
International Isotopes will manufacture the product for Phase III clinical trials; NeoRx will provide $1.3M for pilot plant development; International Isotopes will be responsible for all aspects of manufacturing, including process qualification, quality control, packaging and shipping (2/00) |
PathoGenesis Corp. (PGNS) |
Dompe (Italy) |
TOBI (tobramycin solution for inhalation) for treating infections in patients with cystic fibrosis |
ND |
Dompe will promote and distribute TOBI in Italy (2/00) |
PowderJect Pharmaceuticals plc (UK; LSE: PJP) |
The BOC Group (UK; LSE:BOC) |
Helium micro-cylinder that acts as the PowderJect drug delivery device's internal power source |
ND |
PowderJect worked with BOC on development and pilot manufacturing of the device; under new agreement, BOC will be responsible for construction, management and funding of commercial-scale micro-cylinder production facility, expected to start production in 2002 (1/00) |
Procyon Biopharma Inc.* (Canada) |
Biovail Corp. (Canada) |
Fibrostat, a topical cream for treatment of scars resulting from surgery or burns |
C$1.5 (US$1) |
Agreement commits Biovail to a financing of C$1.5M (US$1M)for completion of development in Canada; upon approval, Procyon will receive an additional C$1M (US$0.7M) milestone, as well as a double-digit percentage royalty on sales; Fibrostat will be developed in collaboration with, and will by marketed by Crystaal, Biovail's Canadian marketing division (2/00) |
Protein Polymer Technologies Inc. (PPTI) |
Femcare Ltd.* (UK) |
Urethral bulking agent for female stress incontinence based on a biomaterial created by combining features of natural silk and human human elastin into a recombinant protein formulation |
$1 |
Femcare will market product in Europe and Australia; Protein Polymer will provide technical assistance and product supplies for Femcare's clinical and regulatory activities for approvals in Europe and Australia; Femcare will pay a $1M licensing fee and royalties on sales; Protein Polymer will provide the product supplies for sales (1/00) |
Ribozyme Pharmaceuticals Inc. (RZYM) |
Avecia LifeScience Molecules (UK) |
Ribozyme manufacturing processes and intellectual property |
ND |
RPI will transfer manufacturing processes and significant intellectual property to Avecia, whose Advanced Medicines manufacturing facilities at Grangemouth, Scotland, will enable both clinical trials and cost-effective commercial manufacture of ribozymes (2/00) |
SkyePharma plc (Canada; SYBB) |
Bioglan Pharma plc (UK) |
Solarase, a topical gel for actinic keratosis that is approved in five member states of the European Union |
ND |
Bioglan will pay a licensing fee and royalties on sales (3/00) |
Synsorb Biotech Inc. |
Tramedico International BV* (the Netherlands) |
Synsorb Pk, designed to prevent serious complications associated with verotoxigenic E. coli infections |
ND |
Tramedico will market and distribute the product in the Netherlands, Belgium and Luxembourg; Synsorb will supply the product and receive an up-front payment, milestones and a share of sales revenue; Tramedico will be responsible >for all costs associated with distribution, marketing and sales (2/00) |
United Therapeutics Corp. (UTHR) |
Paladin Labs Inc. (Canada; TSE:PLB) |
Uniprost, a synthetic variation of the prostacyclin molecule, for treatment of pulmonary hypertension |
ND |
Paladin gains exclusive Canadian distribution rights (2/00) |
Virco* |
Gilead Sciences Inc. (GILD) |
Virco's HIV resistance monitoring tests and services |
ND |
Gilead will promote the Virco portfolio of tests and services to HIV-treating physicians in the U.S.; companies expect to extend collaboration to Europe and Australia (3/00) |
XOMA Ltd. (XOMA) |
Baxter Healthcare Corp. (unit of Baxter International; NYSE:BAX) |
Neuprex, XOMA's Phase III recombinant bactericidal/permeability-increasing protein for treatment of meningococcemia and all future antibacterial and anti-endotoxin indications |
$35 |
Baxter will make up-front and other payments related to the meningococcemia indication totaling $35M; additional payments will be made upon the achievement of development milestones for future indications; Baxter will pay all future clinical development costs, as well as royalties; under separate supply agreement, a XOMA affiliate will manufacture the product; Baxter has future manufacturing rights (1/00) |
Notes: | ||||
# This chart does not include any marketing and/or distribution agreements that involve agricultural product development. The information in the chart covers the time period between 1/1/00 and 3/15/00. | ||||
ND = Not disclosed, reported and/or available | ||||
* Private companies are indicated with an asterisk. | ||||
** The dates listed are the dates of press releases. They are not necessarily the dates on which transactions took place. | ||||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange; LSE = London Stock Exchange |